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A B S T R A C T
Disintegrins are low molecular weight cysteine-rich proteins (4–14 kDa) that are isolated mainly from viperid
snake venom. Due to their potential as lead compounds for binding and blocking integrin receptors, snake venom
disintegrins have become one of the most studied venom protein families. The aim of this study was to obtain
disintegrins from C. totonacus venom and evaluate their capability to bind and block integrin receptors. The C.
totonacus disintegrin fraction (totonacin) represents two disintegrin isoforms obtained from C. totonacus venom.
These disintegrins showed extracellular-matrix (ECM) protein adhesion and migration inhibitory effects on
MDA-MB-231 and HMEC-1 cells. Totonacin (3 μM) inhibited MDA-MB-231 cell adhesion to the ECM proteins,
fibronectin, vitronectin, and laminin by 31.2, 44.0, and 32.1, respectively. Adhesion inhibition to fibronectin,
vitronectin, and laminin observed on HMEC-1 cells was 42.8, 60.8, and 51%, respectively. In addition, totonacin
(3 μM) significantly inhibited MDA-MB-231 and HMEC-1 cell migration (41.4 and 48.3%, respectively).
Totonacin showed more potent cell adhesion inhibitory activity toward vitronectin in both cell lines. These
results suggest a major affinity of totonacin toward αVβ3, α8β1, αVβ5, αVβ1, and αIIbβ3 integrins. In addition, the
inhibitory effect observed on MDA-MB-231 and HMEC-1 cell migration reinforces the evidence of an interaction
between these disintegrins and αVβ3 integrin, which plays a key role in migration and angiogenesis.
1. Introduction
Disintegrins are a non-enzymatic group of small molecules
(4–14 kDa) found in the venom of the Viperidae snake family
(Marcinkiewicz et al., 1999; Galán et al., 2008; Mackessy, 2009). They
are released in venom via the proteolytic processing of PII snake venom
metalloprotease precursors (SVMP) (Kini and Evans, 1992; Shimokawa
et al., 1996). Based on their polypeptide length and the number of
disulfide bonds, disintegrins are classified as long, medium, short,
monomeric, and dimeric molecules (Calvete, 2005; Kim et al., 2005;
Calvete, 2010). In addition, most have an arginine-glycine-aspartic acid
(RGD) motif, which is responsible for binding to integrins (Huang et al.,
1987; Calvete, 2005).
They inhibit various biological activities, such as platelet aggrega-
tion, angiogenesis, metastasis, and tumor growth through their
interaction with various integrins (Marcinkiewicz et al., 2003; Walsh
and Marcinkiewicz, 2011). Disintegrins have shown efficacy in in-
hibiting different tumor cells in in vitro and in vivo cancer models.
Hence, these small peptides have a significant potential as anticancer
agents based on their anti-angiogenic and antimetastatic effects
(Selistre de Araujo et al., 2005; Tian et al., 2007; Ramos et al., 2008;
Sánchez et al., 2009; Minea et al., 2010; Lucena et al., 2012).
Since tigramin was described by Huang et al. (1987), over 100
additional disintegrins have been named and studied (McLane et al.,
2008). Additionally, there are currently two antiplatelet drugs derived
from snake venom disintegrins, tirofiban (Chen et al., 1991; Saudek
et al., 1991) and eptifibatide (Scarborough et al., 1991).
Due to their potential as lead compounds for binding and blocking
integrin receptors, snake venom disintegrins have become one of the
most studied venom protein families (Saviola et al., 2015).
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However, the venom of viperid snakes that are endemic to Mexico
has received little interest, as only two disintegrins from rattlesnake
species endemic to Mexico; basilisin from Crotalus basiliscus venom
(Scarborough et al., 1993a) and morulustatin from C. morulus venom
(Borja et al., 2016) have been studied. This represents ~6% of viperid
species endemic to Mexico (Rivas-Mercado and Garza-Ocañas, 2017).
C. totonacus, a rattlesnake species endemic to Mexico, inhabits the
states of Nuevo Leon, Tamaulipas, San Luis Potosi, Queretaro, Hidalgo,
and Veracruz (Lazcano-Villarreal et al., 2010; Farr et al., 2015). To
date, there have been no studies on the disintegrin content of C. toto-
nacus venom and its biological activity. Therefore, the aim of this study
was to obtain disintegrins from C. totonacus venom and evaluate their
capability to bind and block integrin receptors. We assessed their ability
to inhibit cell adhesion to the extracellular matrix (ECM) proteins, fi-
bronectin, vitronectin, and laminin on the human endothelial cell line,
HMEC-1, and the human breast cancer cell line, MDA-MB-231, and
evaluated their inhibitory activity on cell migration.
2. Materials and methods
2.1. Snakes and venom collection
Six adult C. totonacus rattlesnakes were collected; four in the city of
Juarez, one at Cerro de la Silla (Saddle Hill), Nuevo León state, and one
in the city of Victoria, Tamaulipas state (SEMARNAT license SGPA/
DGVS/05710/16). Three adult C. totonacus rattlesnakes were also
provided from the HerpMx Herpetological Collection (SEMARNAT li-
cense SGPA/DGVS/05710/16). Venom was manually extracted from
each snake using 50 mL plastic tubes (Falcon) covered with parafilm.
Individual venom samples were recovered using 20 mM ammonium
acetate and centrifuged (12,000 g at 10 °C, for 3 min) to remove cell
debris and insoluble material. Samples were maintained at−70 °C and
later freeze-dried and weighed. For the preparation of venom pools,
aliquots of equal amounts of the dry venom of each specimen were
thoroughly mixed.
2.2. Protein quantification
Protein concentrations were determined at 280 nm using an ex-
tinction coefficient of 1 mg/mL. A BioMate 3S UV–Visible spectro-
photometer (Thermo Scientific, Waltham, MA, USA) was used to mea-
sure absorbance.
2.3. Disintegrin purification
2.3.1. Size exclusion chromatography (SE-LC)
A total of 160 mg of crude C. totonacus venom dissolved in 1.5 mL of
20 mM ammonium acetate buffer was fractionated in a Sephadex G-75
(Sigma-Aldrich, St. Louis, MO, USA) in a glass column (1.2 × 2.0 cm)
and equilibrated with the same buffer at a flow rate of 14 mL/h.
Fractions were collected using a Bio-Rad Model 2128 Fraction Collector
(Hercules, CA, USA) at ~0.9 mL/tube, with absorbance monitored at
280 nm. An SE-LC fraction containing low molecular mass proteins
evaluated by Sodium dodecyl-sulfate-plyacrylamide gel electrophoresis
(SDS-PAGE) was collected and lyophilized for further purification.
2.3.2. Reverse-phase high-performance liquid chromatography (RP-HPLC)
The fraction containing low molecular mass proteins obtained from
SE chromatography was further fractionated by RP-HPLC using a C18
column (Grace, Columbia, MD, USA, 4.6 × 250 mm; particle size:
5 μm) equilibrated with solution A (H2O containing 0.1% tri-
fluoroacetic acid (TFA)). Elution was performed at 1 mL/min using a
gradient against solution B (CH3CN containing 0.1% TFA) as follows:
0% B for 5 min, 0 to 15% B over 10 min, 15 to 45% B over 60 min, 45 to
70% B over 10 min, and 70% B for 9 min. Absorbance was monitored at
214 nm (Castro et al., 2013).
2.3.3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE)
Samples of 15 μg SE-LC or 3 μg RP-HPLC fractions were analyzed by
SDS-PAGE under reducing (β-mercaptoethanol) conditions as described
by Laemmli (1970). A polyacrylamide concentration of 15% was em-
ployed. Samples were boiled (~90 °C) prior to running on the gel. Gels
were stained with Coomassie Brilliant Blue G-250. Molecular weight
markers were included in each electrophoretic run.
2.3.4. Inhibition of ADP-induced platelet aggregation
Inhibition of ADP-induced platelet aggregation by disintegrins was
evaluated according to methods described by Angulo et al. (2014).
Briefly, platelet rich plasma was prepared by centrifugation at 50 g for
15 min. Platelet counts were performed using a Sysmex XE automated
equipment (Milton Keynes, UK) and platelet rich plasma (PRP) was
diluted with platelet poor plasma (PPP), prepared by centrifuging blood
at 850 g for 30 min to obtain a concentration of 3 × 108 platelets/mL.
Aliquots of 225 μL PRP were incubated at 37 °C with various con-
centrations of disintegrin (37, 75, 150, and 300 nM) for 5 min with
stirring at 600 rpm. Then, platelet aggregation was initiated by the
addition of 25 μL of the agonist (to achieve the final concentration of
20 μM ADP) and monitored by the increase in light transmittance signal
using a model AggRAM aggregometer (Helena Laboratories, TX, USA)
interfaced to a chart recorder during 5 min. PPP (225 μL) alone was
utilized as a blank, whereas PRP (225 μL) incubated only with ADP was
utilized as a positive control for aggregation.
2.4. Protein sequencing
The fraction containing low molecular mass proteins that produced
an inhibitory effect on ADP-induced platelet aggregation was used for
protein sequencing. The fraction was reduced by dithiothreitol and al-
kylated with iodoacetamide (Weldon and Mackessy, 2009). The protein
was digested using endoproteinase Lys-C (Sigma-Aldrich). Briefly, the
alkylated protein was resuspended in digestion buffer (25 mM Tris/
HCl + 1 mM EDTA, pH 8.5) and 10 μL of Lys-C (0.1 μg/μL) was added
before incubation for 8 h at 37 °C. Digested peptides were purified by
RP-HPLC and their molecular masses were obtained using a Finnigan
LCQFleet mass spectrometer (Thermo Scientific, San Jose, CA, USA)
with an electrospray ionization system as previously described
(Guerrero-Garzón et al., 2018). The amino acid sequence of the N-
terminal section of the native protein, as well as the digested peptides,
was achieved using Edman degradation in a PPSQ-31A Protein Se-
quencer from Shimadzu Scientific Instruments, Inc. (Columbia, MD,
USA). Each peptide (approximately 250 pmol) was adsorbed on a TFA-
treated Glass Fiber Disk, distributed by Shimadzu. The sequence of the
previously described disintegrin, tzabcanin, (Saviola et al., 2015) was
used as a reference. In silico digestion of this sequence was performed
using the Expasy PeptideMass tool (https://web.expasy.org/peptide_
mass/).
2.5. Cell lines and culture conditions
The human mammary gland adenocarcinoma cell line (MDA-MB-
231) and the human endothelial cell line (HMEC-1) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA, USA). The
MDA-MB-231 cells were cultured in L-15 Leibovitz medium supple-
mented with 10% fetal bovine serum (FBS) and incubated at 37 °C in a
humidified CO2-free air incubator. HMEC-1 cells were cultured in
MCDB-131 medium supplemented with 10% FBS containing 1 μg/mL
hydrocortisone and 10 ng/mL epidermal growth factor (Sigma-Aldrich)
and incubated at 37 °C in a humidified atmosphere of 5% CO2.
2.6. Cytotoxicity assay
To determine the optimal concentration of totonacin required,
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MDA-MB-231 and HMEC-1 cells were exposed to totonacin and cyto-
toxicity was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay as described by Mosmann (1983).
Cells were trypsinized and resuspended in complete media at a con-
centration of 2.0 × 105 cells/mL and 100 μL per well of the cell sus-
pension was seeded in 96-well plates. Cells were treated with totonacin
at concentrations of 0.09, 0.18, 0.37, 0.75, 1.5, 3, 6, and 12 μM or PBS
pH 7.4 (control group) and then incubated for 24 h at 37 °C. After
incubation, 100 μL of MTT reagent (Sigma-Aldrich) dissolved in each
cell culture medium (0.5 mg/mL) was added to the cells for a 3 h in-
cubation at 37 °C. MTT was removed and 200 μL of isopropyl alcohol
and 0.4 N HCl were added. The plate was stored at room temperature
(25 °C) in the dark for 30 min and absorbance was read at 570 nm using
an HTS 7000 Bio Assay Reader (Perkin Elmer, Waltham, MA, USA). Cell
cytotoxicity was expressed as a percentage of the viable cell number
compared to the control (non-treated cells) (Zakraoui et al., 2016).
Assays at each totonacin concentration were performed in triplicate and
the experiment was repeated three times.
2.7. Cell adhesion inhibition assay
Inhibition of MDA-MB-231 and HMEC-1 cells binding to fibronectin,
vitronectin, and laminin induced by totonacin was measured as de-
scribed by Wierzbicka-Patynowski et al. (1999), Sánchez et al. (2006),
and Lima-dos-Santos et al. (2015). Triplicate wells of a 96-well plate
were coated with 100 μL of either fibronectin (1 μg per well), vi-
tronectin (1 μg per well), or laminin (1 μg per well) in 0.01 M PBS,
pH 7.4, and incubated overnight at 4 °C. The ECM protein-coated wells
were then blocked by adding 200 μL of specific cell culture medium
containing 2% bovine serum albumin (BSA) (blocking solution). Sub-
sequently, the plate was incubated at 37 °C for 1.5 h. Cells were har-
vested with 0.25% trypsin, counted, and resuspended in a medium
containing 1% BSA at 5 × 105 cells/mL. Thereafter, totonacin was
added to the cell suspension at various concentrations (0.09, 0.18, 0.37,
0.75, 1.5, and 3 μM) and allowed to incubate at 37 °C for 2 h. The
blocking solution was aspirated and preincubated cell/totonacin ali-
quots (100 μL) were seeded in the fibronectin, vitronectin, and laminin-
coated wells and incubated for 2 h at 37 °C. The negative control
consisted of MDA-MB-231 or HMEC-1 cells incubated with PBS. In the
negative control wells, cells were bound to fibronectin, vitronectin, and
laminin. The wells were washed three times with culture medium
containing 0.2% BSA and 200 μL of L-15 medium containing 1% BSA
and 1.5 mg/mL MTT was added to the cells for a 3-h incubation at
37 °C. A total of 100 μL of dimethyl sulfoxide was added for cell lysis.
The plate was gently shaken and absorbance was read at 570 nm using
an HTS 7000 Bio Assay Reader (Perkin Elmer). Percent inhibition was
calculated with the following formula: [(absorbance of negative control
- absorbance of cell/totonacin disintegrins sample)/absorbance of ne-
gative control] × 100. Assays at each totonacin concentration for all
cell lines were performed in triplicate and the experiment was repeated
three times.
2.8. Wound healing assay
To measure the effect of totonacin on MDA-MB-231 and HMEC-1
cell migration, a modified wound healing assay was carried out as
previously described by Ren et al. (2006) and Galán et al. (2008).
Briefly, cells were plated (2 × 105 cells/mL) in a 96-well microtiter
plate. After overnight incubation at 37 °C, the confluent monolayer was
scratched with a sterile 200 μL pipet tip at the midline of each well. The
detached cells were washed away using the culture medium, which was
followed by the addition of 200 μL of new culture medium supple-
mented with 10% FBS. Cells received 100 μL of PBS 0.01 M, pH 7.4,
which allowed cell migration to occur (control group), or 3 μM of to-
tonacin diluted in the same PBS buffer. Cells were then incubated in a
humidified chamber at 37 °C and removed from incubation for
microscopic imaging at 0, 12, and 24 h. Percent migration was calcu-
lated using the following equation: [(C × E)/C)] 100, where C corre-
sponds to the distance of cell edge (mm) at zero time of the control and
E is the distance of cell edge (mm) at the final time. Images were
analyzed using ImageJ 1.x software. Assays were performed in tripli-
cate and the experiment was repeated three times.
2.9. Statistical analyses
Cytotoxicity and cell adhesion data were analyzed by analysis of
variance (ANOVA) followed by Tukey's post-hoc test using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA, USA). Cell migration assays
were analyzed with the Student's t-test by comparing the percent mi-
gration of treatment to the percent migration of the control at the re-
spective time interval. P values< .05 were considered statistically
significant.
3. Results
3.1. Disintegrin purification
The isolation of C. totonacus venom disintegrins was achieved by a
two-step chromatographic separation. Seven fractions were collected by
SE-LC and the electrophoretic protein band profile for each fraction was
evaluated by SDS-PAGE. Fraction 5 had two low-molecular mass bands
within the mass range for disintegrin (4–14 kDa) (Huang et al., 1987;
Scarborough et al., 1993a; Marcinkiewicz et al., 1999; Zhou et al.,
2000) (Fig. 1). Therefore, SE-LC fraction 5 was further fractionated by
RP-HPLC. As a result, 14 fractions were obtained. Fractions 5, 6, 7, 8,
and 9, eluted from 22 to 36 min, aligned with the retention times re-
ported for snake venom disintegrins and had an SDS-PAGE single pro-
tein band of ~14 kDa (Fig. 2). RP-HPLC fractions 5, 7, and 8 inhibited
ADP-induced platelet aggregation, a disintegrin activity (Fig. 3) and
inhibitory concentrations (IC50) of the fractions 5, 7, and 8 were
300 nM, 100 nM, and 72 nM, respectively. Fraction 8 was identified as
the most potent and the most abundant. Therefore, fraction 8 was
further analyzed by mass spectrometry, which revealed the presence of
two protein isoforms with slightly different masses, 7437 and 7218 Da
(Fig. 4).
Regarding protein sequencing, the N-terminal sequence obtained for
the RP-HPLC fraction 8 was GEECDCGSPANPCCDAATCKLR. A sub-
sequent NCBI Protein BLAST analyses indicated that the N-terminal
sequence obtained belonged to the disintegrin family. The reduction of
the RP-HPLC fraction 8 with endoproteinase Lys-C yielded four peptides
with the following molecular masses: P1, 2258.4 Da; P2, 3485.5 Da; P3,
3357.1 Da; and P4, 2425.2 Da. Peptides P1 and P4 had molecular
Fig. 1. Size exclusion chromatography of C. totonacus crude venom. A total of
160 mg of venom was fractionated on a Sephadex G-75. Fractions were ana-
lyzed by SDS-PAGE (A) reducing conditions (B) No reducing conditions.
Fraction 5 showed protein bands within the disintegrin molecular mass range
(4–14 kDa). Fractions 6 and 7 did not show bands.
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masses identical to those of the theoretical peptides of tzabcanin
[C0HK50]. Edman degradation of P2 and P3 yielded the following se-
quence, KKGTVCRPARGDWNDDTCTGQSADCPRNGLYG (Fig. 5-A). The
difference in peptide masses can be explained by the initial double ly-
sine. Complete amino acid sequence comparison using the UniProt
database confirmed that this medium-size C. totonacus disintegrin
contains the RGD binding motif (Fig. 5-B). To identify RP-HPLC fraction
8 as the RGD disintegrin obtained from C. totonacus venom and for
study purposes, this fraction was referred to as totonacin.
3.2. Cytotoxicity
The effect of totonacin on MDA-MB-231 and HMEC-1 cells was
evaluated by the MTT assay. Treating cells with totonacin (0.09, 0.18,
0.37, 0.75, 1.5, 3, 6, and 12 μM) for 24 h caused a dose-dependent
decrease in cell viability. Totonacin at 6 and 12 μM decreased cell
viability by 31.9 and 48.7% in MDA-MB-231 and 32.7 and 44.8% in
HMEC-1 cells (P < .05), respectively. At 3 μM and lower
Fig. 2. RP-HPLC of SE-LC fraction 5; 1.5 mg was injected into a C18 Grace Vydac column; fractions collected between 22 and 38 min (fraction 5 to 12) were analyzed
by SDS-PAGE under β-mercaptoethanol-reducing conditions; in addition to disintegrin activity, fraction 8 (~14 kDa) showed a more prominent peak than fractions 5
and 7.
Fig. 3. Inhibition of platelet aggregation by disintegrins from C. totonacus
venom. Only RP-HPLC fractions 5, 7, and 8 (F5, F7, and F8) showed inhibitory
activity toward platelet aggregation. F8 showed more relative abundance and
potency; thus, was selected for cell assays. ADP 20 μM was used as the platelet
aggregation agonist. Results are presented as mean ± SD (n = 3).
Fig. 4. Mass spectrometry analysis revealed two proteins in disintegrin mass range: 7.2 and 7.4 kDa.
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concentrations, totonacin resulted in a cell viability> 85% (Fig. 6).
Therefore, the 3 μM concentration was selected as the highest con-
centration to evaluate the inhibitory activities of totonacin on fi-
bronectin, vitronectin, and laminin cell adhesion as well as perform cell
migration assays.
3.3. Cell adhesion inhibition assay
At the 3 μM concentration, totonacin inhibited MDA-MB-231 and
HMEC-1 cell adhesion to vitronectin, laminin, and fibronectin ECM
proteins by 44%, 32.1%, and 31.2% and 60.8%, 51.1%, and 42.8%,
respectively. Significant adhesion inhibitory activity toward vitronectin
was observed in both cells as shown in Fig. 7.
3.4. Wound healing assay
Cell migration was measured after scraping cells from the bottom of
wells, following an in vitro wound healing assay. After 24 h of in-
cubation, 3 μM totonacin significantly inhibited MDA-MB-231 and
HMEC-1 cell migration by 41.4 ± 9% and 48.3 ± 5%, respectively
(Fig. 8).
4. Discussion
In this study, a fraction (totonacin), of C. totonacus venom, con-
taining two disintegrin isoforms, with masses of 7437 and 7218 Da, was
identified from pooled venom. According to the molecular masses,
amino acid sequence length, and cysteine content, totonacin was clas-
sified as a medium-size disintegrin. Totonacin shares high amino acid
Fig. 5. (A) Amino acid sequence obtained by EDMAN degradation of RP-HPLC Fraction 8 (totonacin) after digestion with endoproteinase Lys-C and overlapping
peptides. Peptides in black were completely sequenced by Edman degradation, the sequence of peptides in blue was deduced from their molecular weight, based on
the sequence of tzabcanin. (B) Amino acid comparison of totonacin sequence with selected disintegrins: horridistatin, C. horridus (P0C7X6); durissin, C. durissus
(P68521); crotatroxin, C. atrox (P68520); mojastin-2, C. scutulatus (P0C7X7); simusmin, C. simus (C0HJM4); tzabcanin, C. tzabcan (C0HK50); basilicin, C. basiliscus
(P31981); and molossin, C. m. molossus venom (P31984). One-letter code for amino acids is used. Cysteine residues are green marked, RGDW and RGDN binding
motifs are red and yellow marked, respectively. Numbers on the right side correspond to the sequence identity percentage of each selected disintegrin compared to
totonacin. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Cytotoxicity effect on MDA-MB-231 and HMEC-1 cells after 24 h exposure to different totonacin concentrations. Results are presented as mean ± SD (n = 3).
Only 6 μM (*P < .05) and 12 μM (***p < .001) showed significant toxicity when compared to control group. Assays at each concentration of totonacin were
performed in triplicate and the experiment was repeated three times.
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sequence identity with disintegrins of the genus Crotalus. For instance,
it shares a 100% amino acid identity with the disintegrin horridistatin
(Galán et al., 2005), 99% with durissin and crotatroxin (Scarborough
et al., 1993a), 97% with mojastin 2 (Sánchez et al., 2006) and simusmin
(Angulo et al., 2014), and 92% with tzabcanin (Saviola et al., 2015)
(Fig. 5-B).
All fractions obtained by the initial reverse phase chromatography
were originally screened for the activity of inhibition of platelet ag-
gregation. The purpose of this step was to target small proteins, such as
disintegrins (Galán et al., 2005; Sánchez et al., 2006). Disintegrins have
an important functional role in envenomated prey discrimination
(Saviola et al., 2013), as well as promoting hemorrhage to allow
components such as SVMP to spread through the tissues to exert its
enzymatic action and disrupt in cell-cell and cell-extracellular matrix
interactions (McLane et al., 1994). However, isolated disintegrins are
generally non-toxic components of venoms (Walsh and Marcinkiewicz,
2011).
The RGD binding motif was observed as a part of the totonacin
amino acid sequence. The biological activity of disintegrin molecules is
based on the chemical interactions among the amino acids of the RGD
binding motif, C-terminal domain, and cell receptor (Wierzbicka-
Patynowsky et al. 1999; Calvete et al., 2005). Additionally, RGD amino
acid sequences can be further classified as RGDW i.e., totonacin, hor-
ridistatin, durissin, crotatroxin, mojastin-2, and simusmin or RGDN i.e.,
Fig. 7. Inhibition of MDA-MB-231 and HMEC-1 cell adhesion to fibronectin (FN), vitronectin (VN), and laminin (LN). Cells were treated with various concentrations
of totonacin prior to seeding in 96-well microplates. The control group consisted of cells incubated with PBS buffer. Results are presented as mean ± SD (n= 3), all
P values< .05 were considered significant.
Fig. 8. Inhibition of MDA-MB-231 and HMEC-1 cell migration with 3 μM totonacin by wound healing assay. The migration percentage was quantified by multiple
measurements of the width of the scrape space and images analyzed using Image J software. Results are presented as mean ± SD (n = 3), P values< .05 were
considered significant.
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tzabcanin, basilicin, and molossin (Fig. 5-B). Disintegrins expressing the
RGDW domains often display high affinity to αIIbβ3 integrins, whereas
those with RGDN display higher selectivity toward α5β1 and αvβ3 in-
tegrins (Scarborough et al., 1993b; Marcinkiewicz et al., 1997; Juárez
et al., 2008).
Because disintegrins can inhibit the adhesion of cultured cells to
surfaces coated with ECM proteins (Lima-dos-Santos et al., 2015), this
study evaluated the inhibitory effect of totonacin against MDA-MB-231
and HMEC-1 cell adhesion to fibronectin, vitronectin, and laminin ECM
proteins. HMEC-1 cells, commonly used in angiogenesis studies, express
key integrins, including α1, 2, 3, 4, 5, 6, and v, as well as β1, 3, 4, and
5. MDA-MB-231 cells, commonly used in the study of cancer, express
high levels of β1 and αv integrins and β5 and αvβ5 integrins (Taherian
et al., 2011; Lucena et al., 2012; Minea et al., 2012). Therefore, these
cell lines have been used to evaluate the inhibitory effect of disintegrins
on cell adhesion to ECM proteins, as well as cell migration inhibition by
totonacin.
As totonacin showed low cytotoxicity levels at concentrations of
0.09 to 3 μM, this disintegrin concentration range was selected for
biological activity assays. Totonacin had a significant inhibitory effect
on the adhesion of HMEC-1 and MDA-MB-231 cells to vitronectin.
Similar results were reported by Saviola et al. (2016), who found that
tzabcanin from C. tzabcan venom inhibits cell adhesion to vitronectin
(~70%) in A-375 cells. As totonacin showed major adhesion inhibition
activity toward vitronectin in both MDA-MB-231 and HMEC-1 cells,
and as vitronectin targets αVβ3, α8β1, αVβ5, αVβ1, and αIIbβ3 integrins
(Barczyk et al., 2010), totonacin antagonized one or more of the five
integrin vitronectin receptors (αVβ3, α8β1, αVβ5, αVβ1, and αIIbβ3). The
minor cell adhesion inhibitory effect observed toward fibronectin and
laminin could be explained by the greater number of integrins involved
in cell adhesion to each of the ECM proteins. Fibronectin can target nine
integrins: αIIbβ3, α4β1, α4β7, α5β1, α8β1, αvβ1, αvβ3, αvβ6, and αvβ8,
whereas laminin targets seven: α1β1, α2β1, α3β1, α6β1, α7β1, α10β1, and
α6β4 (Saviola et al., 2016). Totonacin caused more inhibitory activity
on cell adhesion to vitronectin than tzabcanin. C. totonacus disintegrins
inhibited cell migration by 41.3% and 48.35% in MDA-MB-231 and
HMEC-1 cells, respectively (Fig. 8), suggesting an αvβ3 integrin
blockade, without excluding other possible integrins that might be
targeted by totonacin, such as αvβ5, which is highly expressed in MDA-
MB-231 cells and has been reported to mediate cancer cell migration
(Pecheur et al., 2002; Rolli et al., 2003; Dang et al., 2006; Sloan et al.,
2006; Taherian et al., 2011). Similar results on cell migration inhibition
have been reported for contortrostatin, r-viridistatin 2, r-mojastin 1,
vicrostatin, and crotatroxin 2 (Swenson et al., 2004; Galán et al., 2008;
Minea et al., 2012; Lucena et al., 2015).
5. Conclusion
This study is the first to describe the isolation, determination of
mass and amino acid sequence, and biological activities of disintegrins
from C. totonacus venom. Overall, results obtained for C. totonacus
disintegrin totonacin show its capacity to disrupt cell-ECM protein in-
teraction, ability to inhibit cell migration, and potential as an anti-
metastatic agent. As disintegrins in C. totonacus venom were obtained at
concentrations below 1%, recombinant expression of this disintegrin
should be continued to obtain higher amounts. In addition, evaluations
of the effects of totonacin should be continued with in vivo models.
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